L-AP6

Discontinued Product

0341 has been discontinued.

View all Miscellaneous Glutamate products.
说明: Selective agonist of the 'quis' effect
化学名: L-(+)-2-Amino-6-phosphonohexanoic acid
说明书
引用文献
评论
文献 (3)

生物活性 for L-AP6

L-AP6 is a selective agonist for 'quis'-sensitized site.

技术数据 for L-AP6

分子量 211.15
公式 C6H14NO5P
储存 Store at RT
CAS Number 78944-89-5
PubChem ID 3062646
InChI Key QIOXWRQXHFVNLV-YFKPBYRVSA-N
Smiles [H][C@@](CCCCP(O)(O)=O)(N)C(O)=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

关键词: L-AP6, L-AP6 supplier, Selective, agonists, quis, effect, Glutamate, mGlur, Receptors, Metabotropic, iGluR, Ionotropic, Miscellaneous, 0341, Tocris Bioscience

篇 L-AP6 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 L-AP6 的引用文献。

L-AP6 的评论

目前没有该产品的评论。 Be the first to review L-AP6 and earn rewards!

Have you used L-AP6?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Metabotropic Glutamate Receptors Scientific Review

Metabotropic Glutamate Receptors Scientific Review

Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.